TrialBlood advances2024

Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease.

Santosh L Saraf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.